Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCA2PJ)

• Drug Name: ONO-2506 Drug Info
• Synonyms: (2R)-2-Propyloctanoic acid; Arundic acid; 185517-21-9; (R)-2-PROPYLOCTANOIC ACID; Proglia; Cereact; ONO 2506; R-(-)-Arundic Acid; UNII-F2628ZD0FO; MK-0724; (R)-(-)-2-Propyloctanoic Acid; F2628ZD0FO; NCGC00183861-01; Acide arundique; Acido arzndico; Acidum arundicum; Arundic acid [INN]; Arocyte; Acide arundique [INN-French]; Acidum arundicum [INN-Latin]; Arundic acid (JAN/INN); Acido arzndico [INN-Spanish]; ONO-2506PO; MK 0724; AC1L4LMD; AC1Q5QIF; SCHEMBL4365; DSSTox_RID_83036; DSSTox_CID_28767; DSSTox_GSID_48841; ONO 2506PO; Arocyte; Ono2506; Acido arundico [INN-Spanish]; 2-Propyloctanoic acid; FR149175

Indication

Disease Entry	ICD 11	Status	REF
Stroke	8B20	Phase 2/3	[1]
Type-2 diabetes	5A11	Terminated	[2]

• Cross-matching ID:
  PubChem CID: 208925
  CAS Number: CAS 185517-21-9
  TTD Drug ID: DMCA2PJ

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-3 (ADRB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mirabegron	DMS1GYT	Overactive bladder	GC50.0	Approved	[5]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[6]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[7]
Bopindolol	DMIFYLX	Hypertension	BA00-BA04	Approved	[8]
Mepindolol	DMUDWP9	Angina pectoris	BA40	Approved	[9]
Rimiterol	DMA47C6	Asthma	CA23	Approved	[10]
Bitolterol	DMK6XAV	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Nipradilol	DMA65ER	Angina pectoris	BA40	Approved	[12]
Vibegron	DMFR201	Overactive bladder	GC50.0	Approved	[13]
CL-316,243	DMXH1KC	Obesity	5B81	Phase 2	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Agonist	[3]
S100 calcium-binding protein B (S100B)	TTQ0V86	S100B_HUMAN	Modulator	[4]

References

• [1] ClinicalTrials.gov (NCT00229177) Study of ONO-2506 in Patients With Acute Ischemic Stroke. U.S. National Institutes of Health.
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008959)
• [3] FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12.
• [4] Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42.
• [5] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [6] Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21.
• [7] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [8] Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3.
• [9] Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3.
• [10] Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8.
• [11] Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37.
• [12] Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49.